GlaxoSmithKline Inc.

Meetings over time

• May 20255 meetingsRuby Sahota, Ritu Banerjee, Rodrigo Arancibia, Jacqueline Arthur, Kanchana Amaratunga
  May 2025: 5 meetings, with Ruby Sahota, Ritu Banerjee, Rodrigo Arancibia, Jacqueline Arthur, Kanchana Amaratunga
• Jun 20255 meetingsKyle Fox, Pavan Sapra, Rodrigo Arancibia, Helena Jaczek
  Jun 2025: 5 meetings, with Kyle Fox, Pavan Sapra, Rodrigo Arancibia, Helena Jaczek
• Jul 202511 meetingsNeeraj Bhalla, Natasha Beg, Joseph Nesrallah, Galen Richardson, Lisa Jorgensen
  Jul 2025: 11 meetings, with Neeraj Bhalla, Natasha Beg, Joseph Nesrallah, Galen Richardson, Lisa Jorgensen
• Aug 20250 meetings
  Aug 2025: 0 meetings
• Sep 20253 meetingsPhilip Jennings, Ritu Banerjee, Paul Moen, Manuela Tomic, Iqra Khalid
  Sep 2025: 3 meetings, with Philip Jennings, Ritu Banerjee, Paul Moen, Manuela Tomic, Iqra Khalid
• Oct 20252 meetingsRachael Thomas, Warren Steinley
  Oct 2025: 2 meetings, with Rachael Thomas, Warren Steinley
• Nov 202511 meetingsjeff kibble, Burton Bailey, Fabien Lengelle, Jessica Halverson, Elaine Chong
  Nov 2025: 11 meetings, with jeff kibble, Burton Bailey, Fabien Lengelle, Jessica Halverson, Elaine Chong
• Dec 20250 meetings
  Dec 2025: 0 meetings
• Jan 20261 meetingRodrigo Arancibia
  Jan 2026: 1 meeting, with Rodrigo Arancibia
• Feb 20261 meetingJean-Yves Duclos
  Feb 2026: 1 meeting, with Jean-Yves Duclos
• Mar 20264 meetingsJustine Frame, Rodrigo Arancibia
  Mar 2026: 4 meetings, with Justine Frame, Rodrigo Arancibia
• Apr 20266 meetingsJustine Frame, Manuela Tomic, Rodrigo Arancibia, Ritu Banerjee, Fern Bannatyne
  Apr 2026: 6 meetings, with Justine Frame, Manuela Tomic, Rodrigo Arancibia, Ritu Banerjee, Fern Bannatyne
• May 20263 meetingsRodrigo Arancibia, mohamed djeffal, Jean-Yves Duclos, maya ben kaled, Anie-eve corbin
  May 2026: 3 meetings, with Rodrigo Arancibia, mohamed djeffal, Jean-Yves Duclos, maya ben kaled, Anie-eve corbin
• Jun 20264 meetingsMackenzy Metcalfe, Manuela Tomic, Justine Frame, mohamed djeffal, Jocelyn Milburn
  Jun 2026: 4 meetings, with Mackenzy Metcalfe, Manuela Tomic, Justine Frame, mohamed djeffal, Jocelyn Milburn
• Jul 20265 meetingsJacqueline Kosche, sylvia haertel, Kabisan Thanendran, chanel sterie, Justine Frame
  Jul 2026: 5 meetings, with Jacqueline Kosche, sylvia haertel, Kabisan Thanendran, chanel sterie, Justine Frame

Hover or focus a month to see who was met.

What they lobby about

• Health60
• Economic Development42
• Government Procurement26
• Budget18
• Industry15
• Research and Development14
• International Trade13
• Immigration7
• Defence4
• Intellectual Property4
• Internal Trade4
• Consumer Issues1
• Justice and Law Enforcement1

The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.

Who they met

The 40 most-met of 52 people named in these filings.

Innovation, Science and Economic Development Canada (ISED) (29) · House of Commons (18) · Health Canada (HC) (13) · Public Health Agency of Canada (PHAC) (9) · Immigration, Refugees and Citizenship Canada (IRCC) (4) · Finance Canada (FIN) (4)

In their own words

• The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements.
• Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB are consistent with the mandate assigned by Parliament.
• Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada.